Italfarmaco hires Maxer to implement its 2021 Clinical Trial Disclosure program

We are pleased to announce that Italfarmaco S.p.A. has entrusted Maxer Consulting to implement the Clinical Trial Disclosure program for 2021.

The program requires Maxer to carry out the necessary activities to ensure Italfarmaco’s compliance with the regulations in force in the European Union (EU Reg. 536/2014) and the United States (FDAAA 801, Final Rule) and the transparency of clinical studies’ results.

The program foresees that Maxer updates Italfarmaco on the imminent release of the EMA Clinical Trial Information System (CTIS) platform and its impact on the clinical development operations.